Synthesis of 2',3'-dideoxy-3'-hydroxymethylcytidine: A novel hydroformylation route

Tetrahedron Letters

Volumn 38, Issue 9, 1997, Pages 1509-1510

  Kaldor, Stephen W ^a   Fritz, James E ^a   Ward, Jeffrey A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 3' HYDROXYMETHYLCYTIDINE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DRUG SYNTHESIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STEREOCHEMISTRY;

EID: 0031550894     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(97)00142-1     Document Type: Article

References (26)

1. 1. Svansson, L.; Kvarnstrom, I.; Classon, B.; Samuelsson, B. J. Org. Chem. 1991, 56, 2993-2997.
2. 2. (a) Shragami, H.; Irie, Y.; Shirae, H.; Yokozeki, K.; Yasuda, N. J. Org. Chem. 1988, 53, 5170-5173.
3. (b) Manchand, P. S.; Belica, P. S.; Holman, M. J.; Huang, T.-N.; Maehr, H.; Tam S. Y.-K.; Yang, R. T. J. Org. Chem. 1992, 57, 3473-3478.
4. For other preparations of nucleoside 2′,3′-olefins see (c) Clive, D. L. J.; Wickens, P. L.; Sgarbi, P. W. M. J. Org. Chem. 1996, 61, 7426-7437
5. 3. (a) Siegel, H.; Himmele, W. Angew. Chem. Int. Ed. Engl. 1980, 19, 178-183.
6. (b) Hanson, B. E.; Davis, M. E. J. Chem. Ed. 1987, 64, 928-930.
7. (c) Pruett, R. L.; Smith, J. A. J. Org. Chem. 1969, 34, 327-330.
8. (d) Botteghi, C.; Ganzerla, R.; Lenarda, M.; Moretti, G. J. Mol. Catal. 1987, 40, 129-182.
9. (e) Pruett, R. L. Ann. N. Y. Acad. Sci. 1977, 295, 239-248.
10. (f) Pruett, R. L. Adv. Organomet. Chem. 1979, 17, 1-60.
11. (g) Pruett, R. L. J. Chem. Ed. 1986, 63, 196-198.
12. 4. Polo, A.; Fernandez, E.; Claver, C.; Castillon, S. J. Chem. Soc., Chem. Commun. 1992, 639-640.
13. 5. Moser, H. E. Strategies and Chemical Approaches Towards Oligonucleotide Therapeutics. In Perspectives in Medicinal Chemistry; Testa, B.; Fuhrer, W.; Kyburz, E.; Giger, R. (Eds.) VCH Publishers, Inc.: New York, 1993; pp 275-297.
14. 6. (a) Burke, S. D.; Cobb, J. E.; Takeuchi, K. J. Org. Chem. 1990, 55, 2138-2151.
15. (b) Ojima, I.; Kato, K.; Okabe, M.; Fuchikami, T. J. Am. Chem. Soc. 1987, 109, 7714-7720.
16. (c) Polo, A.; Claver, C.; Castillon, S.; Ruiz, A.Organometallics 1992, 11, 3525-3533.
17. 7. Lazzaroni, R.; Uccello-Barretta, G.; Benetti, M. Organometallics 1989, 8, 2323-2327.
18. 8. (a) Shuto, S.; Iwano, T.; Inoue, H.; Ueda, T. Nucleos. Nucleot. 1982, 1, 263-273.
19. (b) Ward, J. A. unpublished result.
20. 9. (a) Osborn, J. A.; Wilkinson, G.; Young, J. F. J. Chem. Soc., Chem. Commun. 1965, 17.
21. (b) Evans, D.; Osborn, J. A. Wilkinson, G. J. Chem. Soc. (A) 1968, 3133.
22. (c) Slaugh, L. H.; Mullineaux, R. D.; German Patent Application 1,186,455 (1961); U.S. Patent 3,239,566 (1966).
23. 1H NMR analyses for the hydroformylation product 4a.
24. 11. Johnson, C. R. (Ed.) Organic Syntheses, John Wiley and Sons, Inc.: New York, Vol. 57; pp 11-15.
25. 12. Billig, E.; Abatjoglou, A. G.; Bryant, D. R.; U. S. Patents 4,668,651 (1987) and 4,769,498 (1988).
26. 13. Besides eliminating the uracil to cytocine conversion, another advantage in using 3b rather than 3a was that the cytosine moiety exhibited less predisposition toward elimination from 5b.